文献速递肝病消化道肿瘤与早癌

肝移植治疗肝细胞癌风险预测的国际验证:HALTHCC在4,089例患者中的验证

Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients.
PubMed 文献 · Hepatology · 2019-08-19

该国际多中心研究在2002至2014年间纳入北美、欧洲和亚洲16个中心的4,089例肝细胞癌肝移植患者,对术前计算的连续风险评分HALTHCC进行验证和重新校准。重新校准后,HALTHCC对复发的判别能力C-index为0.71,对总生存的判别能力C-index为0.63。研究认为该评分有助于建立全球肝细胞癌候选者的移植前风险分层。

要点

  • HALTHCC使用移植前甲胎蛋白、MELD-Na评分和肿瘤负荷评分计算。
  • 最低风险组(HALTHCC 0-5)血管侵犯率7.7% vs 最高风险组(>35)70.6%,P<0.0001。
  • 重新校准后HALTHCC对复发C-index=0.71,对总生存C-index=0.63。

核心结论

  • 该大型国际研究验证并优化了连续风险指标HALTHCC在建立全球肝细胞癌候选者移植前风险中的作用。
  • 研究认为有必要开展前瞻性试验将HALTHCC引入临床实践。

研究设计与样本

  • 国际多中心队列研究,纳入2002至2014年北美、欧洲和亚洲16个中心的4,089例肝细胞癌肝移植患者,其中符合和不符合米兰标准者均包括(不符合者占25.2%)。
  • 使用移植前甲胎蛋白、MELD-Na评分和肿瘤负荷评分的连续风险评分在随机选择的队列(n=1,021)中重新校准,并在其余患者(n=3,068)中验证。

主要发现

  • 研究显示不同中心和年份之间存在显著异质性,反映过去十年的实践趋势。
  • 移植肝病理上,血管侵犯和低分化成分随HALTHCC评分升高而增加。
  • 最低风险患者(HALTHCC 0-5)的血管侵犯率和低分化成分率均低于最高风险患者(HALTHCC > 35):血管侵犯7.7%[1.2-14.2] vs 70.6%[48.3-92.9],低分化成分4.6%[0.1%-9.8%] vs 47.1%[22.6-71.5],两者P < 0.0001。
  • 该趋势在米兰标准状态中均稳健。
  • 重新校准前,HALTHCC对总生存的判别能力(C-index = 0.61)优于所有既往报告的评分。

关键数值与推荐

  • HALTHCC评分使用移植前甲胎蛋白、MELD-Na评分和肿瘤负荷评分计算。
  • 最低风险组(HALTHCC 0-5)血管侵犯率7.7%[1.2-14.2],最高风险组(HALTHCC > 35)为70.6%[48.3-92.9],P < 0.0001。
  • 最低风险组(HALTHCC 0-5)低分化成分率4.6%[0.1%-9.8%],最高风险组(HALTHCC > 35)为47.1%[22.6-71.5],P < 0.0001。
  • 重新校准前HALTHCC对总生存的C-index = 0.61。
  • 重新校准后HALTHCC对复发的C-index = 0.71,对总生存的C-index = 0.63。

临床怎么用

  • HALTHCC可作为肝细胞癌患者肝移植前的连续风险评分,用于建立移植前风险分层。
  • 该评分基于移植前甲胎蛋白、MELD-Na评分和肿瘤负荷评分计算,可在术前使用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Although Milan Criteria (MC) generalized the practice of LT for HCC and improved outcomes, its predictive character has degraded with increasing candidate and oncological heterogeneity. We sought to validate and recalibrate a previously developed, preoperatively calculated, continuous risk score, the Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALTHCC), in an international cohort. From 2002 to 2014, 4,089 patients (both MC in and out [25.2%]) across 16 centers in North America, Europe, and Asia were included. A continuous risk score using pre-LT levels of alpha-fetoprotein, Model for End-Stage Liver Disease Sodium score, and tumor burden score was recalibrated among a randomly selected cohort (n = 1,021) and validated in the remainder (n = 3,068). This study demonstrated significant heterogeneity by site and year, reflecting practice trends over the last decade. On explant pathology, both vascular invasion (VI) and poorly differentiated component (PDC) increased with increasing HALTHCC score. The lowest-risk patients (HALTHCC 0-5) had lower rates of VI and PDC than the highest-risk patients (HALTHCC > 35) (VI, 7.7%[ 1.2-14.2] vs. 70.6% [48.3-92.9] and PDC:4.6% [0.1%-9.8%] vs. 47.1% [22.6-71.5]; P < 0.0001 for both). This trend was robust to MC status. This international study was used to adjust the coefficients in the HALTHCC score. Before recalibration, HALTHCC had the greatest discriminatory ability for overall survival (OS; C-index = 0.61) compared to all previously reported scores. Following recalibration, the prognostic utility increased for both recurrence (C-index = 0.71) and OS (C-index = 0.63). Conclusion: This large international trial validated and refined the role for the continuous risk metric, HALTHCC, in establishing pre-LT risk among candidates with HCC worldwide. Prospective trials introducing HALTHCC into clinical practice are warranted.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Firl DJ, Sasaki K, Agopian VG, et al. Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology. 2019. PMID: 31243778. doi:10.1002/hep.30838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。